Physician profile
Robert Shogry
NPI 1871574319
$18,254.24
in general payments reported to CMS, 2019-2025
43 companies · $2,682 in 2025
The $2,682 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,192 · 2020: $1,264 · 2021: $2,553 · 2022: $2,502 · 2023: $3,356 · 2024: $2,706 · 2025: $2,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,743.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,612.99 | 2019-2024 | Xarelto |
| Medtronic, INC. | $2,529.03 | 2021-2025 | Symplicity G3, Onyx Frontier |
| E.R. Squibb & Sons, L.L.C. | $1,596.64 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $1,311.73 | 2019-2025 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor, Farapulse |
| Novartis Pharmaceuticals Corporation | $1,272.63 | 2019-2025 | |
| Amgen INC. | $1,197.70 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $1,035.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $756.42 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $573.15 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $547.45 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $546.36 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.24 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $376.23 | 2024-2025 | Ozempic, Wegovy |
| Medtronic Vascular, INC. | $335.87 | 2019-2020 | |
| Amarin Pharma, INC. | $313.29 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $270.50 | 2022-2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $253.66 | 2019-2024 | |
| Bridgebio Pharma, INC. | $201.79 | 2025 | Attruby |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Biotronik INC. | $199.96 | 2019-2020 | |
| Esperion Therapeutics, INC. | $148.80 | 2020-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $140.86 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Kiniksa Pharmaceuticals, LTD. | $136.70 | 2023 | Arcalyst |
| Atricure, INC. | $123.46 | 2019-2021 | |
| Lundbeck LLC | $113.51 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $110.91 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $89.15 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Lilly USA, LLC | $88.20 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $80.28 | 2023-2024 | Inpefa |
| Abbott Laboratories | $76.84 | 2020-2023 | Jot Dx, Mitraclip |
| Regeneron Healthcare Solutions, INC. | $75.22 | 2019 | |
| Akcea Therapeutics, INC. | $65.62 | 2020-2021 | |
| Scpharmaceuticals INC. | $55.68 | 2023 | |
| Misonix INC | $48.34 | 2021 | |
| Alnylam Pharmaceuticals INC. | $42.03 | 2019-2025 | Onpattro |
| Abiomed | $38.42 | 2024 | Impella |
| Teleflex LLC | $31.04 | 2023 | Trapliner |
| Kowa Pharmaceuticals America, INC. | $27.72 | 2019-2021 | |
| Edwards Lifesciences Corporation | $23.54 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Shockwave Medical, INC | $17.64 | 2025 | |
| Philips North America LLC | $15.90 | 2023 | |
| G Medical Diagnostic Services, INC. | $15.71 | 2021 | |
| Corindus INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shogry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.